PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 :
A61K 38/18, 38/19 // (A61K 38/19, 38:18)

A2

(11) International Publication Number: **WO 99/15191**

(43) International Publication Date: 1 April 1999 (01.04.99)

(21) International Application Number: PCT/EP98/06004

(22) International Filing Date: 21 September 1998 (21.09.98)

(30) Priority Data:
97116373.8 19 September 1997 (19.09.97) EP

(71) Applicant *(for all designated States except US)*: BIOPHARM GMBH [DE/DE]; Czernyring 22, D–69115 Heidelberg (DE).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: UNSICKER, Klaus [DE/DE]; Köpfelweg 54, D–69118 Heidelberg (DE). POHL, Jens [DE/DE]; Bastwald 25, D–76707 Hambrücken (DE). PAULISTA, Michael [DE/DE]; Wingertstrasse 10, D–69181 Leimen (DE). BECHTOLD, Rolf [DE/DE]; Carl–Zuckmayr–Strasse 21, D–69126 Heidelberg (DE).

(74) Agent: PERREY, Ralf; Müller–Boré & Partner, Grafinger Strasse 2, D–81671 München (DE).

(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published
Without international search report and to be republished upon receipt of that report.

(54) Title: CYTOKINES HAVING NEUROTROPHIC ACTIVITY

(57) **Abstract**

The present invention relates to a pharmaceutical composition having neurotrophic activity, comprising a biologically active amount of at least two cytokines, wherein at least one of said cytokines is BMP, GDF, TGF–β or GDNF.



A



B

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	**ES**	Spain	**LS**	Lesotho	**SI**	Slovenia
AM	Armenia	**FI**	Finland	**LT**	Lithuania	**SK**	Slovakia
AT	Austria	**FR**	France	**LU**	Luxembourg	**SN**	Senegal
AU	Australia	**GA**	Gabon	**LV**	Latvia	**SZ**	Swaziland
AZ	Azerbaijan	**GB**	United Kingdom	**MC**	Monaco	**TD**	Chad
BA	Bosnia and Herzegovina	**GE**	Georgia	**MD**	Republic of Moldova	**TG**	Togo
BB	Barbados	**GH**	Ghana	**MG**	Madagascar	**TJ**	Tajikistan
BE	Belgium	**GN**	Guinea	**MK**	The former Yugoslav Republic of Macedonia	**TM**	Turkmenistan
BF	Burkina Faso	**GR**	Greece			**TR**	Turkey
BG	Bulgaria	**HU**	Hungary	**ML**	Mali	**TT**	Trinidad and Tobago
BJ	Benin	**IE**	Ireland	**MN**	Mongolia	**UA**	Ukraine
BR	Brazil	**IL**	Israel	**MR**	Mauritania	**UG**	Uganda
BY	Belarus	**IS**	Iceland	**MW**	Malawi	**US**	United States of America
CA	Canada	**IT**	Italy	**MX**	Mexico	**UZ**	Uzbekistan
CF	Central African Republic	**JP**	Japan	**NE**	Niger	**VN**	Viet Nam
CG	Congo	**KE**	Kenya	**NL**	Netherlands	**YU**	Yugoslavia
CH	Switzerland	**KG**	Kyrgyzstan	**NO**	Norway	**ZW**	Zimbabwe
CI	Côte d'Ivoire	**KP**	Democratic People's Republic of Korea	**NZ**	New Zealand		
CM	Cameroon			**PL**	Poland		
CN	China	**KR**	Republic of Korea	**PT**	Portugal		
CU	Cuba	**KZ**	Kazakstan	**RO**	Romania		
CZ	Czech Republic	**LC**	Saint Lucia	**RU**	Russian Federation		
DE	Germany	**LI**	Liechtenstein	**SD**	Sudan		
DK	Denmark	**LK**	Sri Lanka	**SE**	Sweden		
EE	Estonia	**LR**	Liberia	**SG**	Singapore		

"Cytokines having neurotrophic activity"

Description

The present invention relates to a pharmaceutical composition having neurotrophic activity, for treating peripheral and/or CNS-disorders in mammals.

GDF-5 is a bone morphogenetic protein like molecule which, similar to other members of the transforming growth factor beta (TGF-β) superfamily, has been implicated in neurotrophic functions. For example, TGF-β1, -β2, and -β3, as well as activin A, bone morphogenetic proteins (BMP) -2, -4, -6, -7, -12, glial cell line-derived neurotrophic-like factors (GDNF-like), and GDF-5 have all been shown to promote *in vitro* the survival of midbrain dopaminergic neurons by various mechanisms. GDNF also acts on a wide spectrum of peripheral neurons.

The discovery of GDNF as a neurotrophic factor for midbrain dopaminergic neurons was a hallmark in the search for novel molecules that may have relevance in the treatment of neurodegenerative diseases, as e.g. Parkinson's disease. The significance of GDNF is further underscored by its efficacy in several animal models of PD including non-human primates, ubiquitous expression in neurons of the CNS, and its widening spectrum of responsive neuron populations. GDNF signals via the tyrosine kinase receptor c-ret in co-operativity with a GPI-linked α receptor, the GDNFRα. GDNF is a member of the TGF-ß superfamily, its closest relatives being neurturin. Targeted mutations of the GDNF or c-Ret genes have indicated that GDNF is essentially required for the development of the kidney, major portions of the enteric nervous system and the sympathetic superior cervical ganglion. However, GDNF does not support the survival of most peripheral neurons in low-density dissociated cultures and defined media. Follow-up experiments in which GDNF has been shown to promote the survival of enriched peripheral autonomic and sensory neurons were all performed using

serum throughout the whole culture period. Furthermore, the dopaminotrophic effect of GDNF was established in an extremely complex culture system where its most prominent effect did not become apparent until day 7 in culture.

TGF-ßs are widely distributed and contextually acting cytokines with prominent roles in development and cell cycle control. TGF-ßs have been implicated in the regulation of neuronal survival of e.g. motoneurons, sensory and midbrain dopaminergic neurons. It should be noted, however, that TGF-ß shows no or marginal effects on highly enriched, serum-free neuron cultures, as e.g. sensory neurons.

Thus, the technical problem underlying the present invention is to provide a new system having improved neurotrophic activity, for the treatment of peripheral and/or CNS-disorders in mammals.

The solution to the above technical problem is achieved by the embodiments characterized in the claims.

In particular, the present invention relates to a pharmaceutical composition having a neurotrophic activity, comprising a biologically active amount of at least two cytokines or functionally active derivatives or parts thereof and optionally a pharmaceutically acceptable carrier and/or diluent, wherein at least one of said cytokines is BMP, GDF, TGF-ß or GDNF. The term "BMP" includes BMP-2, BMP-4, BMP-6, BMP-7, BMP-11 and BMP-12. The term "TGF-ß" includes TGF-ß1, TGF-ß2 and TGF-ß3. The term "GDNF" includes GDNF, neurturin and persephin. The terms "functionally active derivative" and "functionally active part" refer to a proteinous compound exhibiting at least part of the biological function of the respective cytokine. The cytokines used in the pharmaceutical composition according to the present invention may be selected from the group consisting of GDF such as GDF-5, GDF-6, GDF-7, GDF-8 and GDF-9, GDNF, TGF such as TGF-α or TGF-ß, e.g. TGF-β1, TGF-β2 or TGF-β3, activin A, BMP such as BMP-2, BMP-4, BMP-6, BMP-7, BMP-11, BMP-12, BDNF, NGF, neurotrophines such as NT-3 or NT-4, EGF, CNTF and FGF such as FGF-2.

Preferred embodiments of the present invention the pharmaceutical composition comprise the following combinations: GDF-5 and NGF or NT-3 or GDNF, TGF-ß and GDNF or FGF-2 or CNTF or NT-3 or NGF, NGF and BMP-4 or BMP-12, NT-3 and BMP-2 or BMP-7 or BMP-12.

As a surprising fact, if at least one of BMP, GDF, TGF-ß and GDNF is present in the above defined pharmaceutical composition, a synergistic effect can be observed resulting in an increased neurotrophic activity, as compared to e. g. known compositions without GDF and/or GNDF.

The pharmaceutical composition according to the present invention may be used for the treatment of peripheral and/or CNS-disorders in mammals, preferably in man, such as Parkinson's disease, Alzheimer's disease, ALS or other dementia, other neurodegenerative disorders of the central nervous system and peripheral neuropathies including diabetes, cisplatinium or other genetic or acquired peripheral nerve diseases.

The figures show:

Fig. 1: A comparison of dose-response curves of GDF-5 and NGF in cultures of E8 chick DRG. Data are shown as means ± SEM from three independent experiments with triplicate cultures. *P < 0.05; **P < 0.01 significantly different from untreated negative control values.

Fig. 2: Same experiment as in Fig. 1 except that (A) BMP-2, (B) BMP-4, (C) BMP-6, (D) BMP-7, (E) BMP-11 and (F) BMP-12 have been used in the respective composition.

Fig. 3: Co-treatment of E8 DRG neurons for 48 hours with GDF-5 at a serial dilution range and NT-3 at a constant concentration of 2.5 ng/ml (-··-). For comparison serial dilutions of GDF-5 (-△-) as well as NT-3 (....■...) are given. Surviving neurons were counted in triplicate determinations of at least two independent experiments. Values given are means

+ SEM. Significance was derived from the comparison between neuronal numbers after GDF-5 plus NT-3 (2.5 ng/ml) and the individual factors. *P < 0.05; **P < 0.01.

Fig. 4: Survival of E8 DRG neurons cultured for 48 hours in the presence of various trophic factors at saturating concentrations with or without the addition of GDF-5 at a constant concentration of 20 ng/ml. Values represent the means + SEM of at least two independent experiments with triplicate determinations. *P < 0.05 significant difference from neuronal numbers treated with NGF alone.

Fig. 5: Survival of E8 chick DRG neurons cultured for 48 hours in the presence of saturating conentrations of (A) NGF (10 ng/ml) or (B) NT-3 (10 ng/ml) applied seperately or in combination with the indicated BMPs. Cultures were treated for 48 h. Values given are mean + SEM of quadruplicate determinations of at least two independent experiments. *P < 0.05 significant difference from neuronal numbers treated with NGF or NT-3 alone.

Fig. 6: Survival of peripheral autonomic and sensory neurons by the synergistic action of GDNF and TGF-β. A, chick ciliary ganglionic (CG) neurons; B, dose-response curve for the combined action of GDNF and TGF-β; C, chick dorsal root ganglionic (DRG) neurons; D, chick sympathetic ganglionic (SG) neurons. Neurons from the respective ganglia were isolated at embryonic day 8 (E8) and grown under the indicated conditions. Neurons were maintained in serum containing medium (grey bars; A,C,D) or in serum free medium (white bars: A,B,C,D). In the presence of 10% horse serum addition of a saturating concentration of GDNF promoted survival of each of the three neuron populations at levels identical to those achieved by addition of the respective neurotrophic factor (CNTF for CG, NGF for DRG and SG neurons) to serum-free culture media. Addition of a neutralizing antibody to TGF-β1, -β2, and -β3 reduced neuron survival to levels seen with the addition of

serum alone indicating that GDNF required TGF-ß in the serum to achieve its survival promoting effect. In serum-free conditions, GDNF and TGF-β1, when added by themselves had virtually no survival promoting effect. However, when combined at optimal concentrations, both factors permitted neuron survival at levels identical to those achieved with the established neurotrophic factors CNTF and NGF, respectively.

Fig. 7: Assay as performed in figure 1 using neurons from the respective ganglia of chick E10 (A,B,C) and E12 (D,E,F) embryos. Data indicate that the GDNF/TGF-β synergism also applies to neurons at more advanced stages of development.

Fig. 8: Survival promoting effect of GDNF on rat embryonic mesencephalic dopaminergic neurons (E14) is dependent on the presence of TGF-β. Dissociated cultures were treated with GDNF (10 ng/ml), with GDNF in the presence of anti-TGF-β1, -β2, -β3 (10 μg/ml), with TGF-β3 (2 ng/ml) or without any growth factor added (control) for 8 days in culture. Numbers of dopaminergic neurons were determined by counting the numbers of tyrosine hydroxylase (TH) immunoreactive neurons.

Fig. 9: GDNF requires TGF-β *in vivo* for establishing its neurotrophic effect. Retrogradely labeled preganglionic (IML) neurons to the adrenal medulla (a) express cRet (b) and GFRα-1 (c) mRNAs. Cell death of the preganglionic neurons caused by adrenomedullectomy is fully prevented by substitution of GDNF into the adrenal cavity (d). Co-application of a neutralizing TGF-β antibody significantly reduces neuroprotection by GDNF (e). LF, lateral funiculus of the spinal cord. Bar = 100 μm.

Fig. 10: Mechanisms underlying the synergistic actions of GDNF and TGF-β. (A) Wortmannin, a specific inhibitor of IP3 kinase abolishes GDNF/TGF-β-mediated survival of chick ciliary ganglionic neurons indicating that IP3 kinase is an essential mediator in signal transduction of the combined

action of GDNF and TGF-β. (B) PIPLC, which liberates GPI-anchored cytokine receptors from the plasma membrane interferes, as expected, with the survival promoting effect of CNTF on chick ciliary ganglionic neurons, since CNTF employs a GPI-anchored alpha receptor for signal transduction. PIPLC does not interfere with the survival promoting effect of FGF-2, which does not employ an alpha receptor for signaling. Treatment of isolated ciliary neurons with PIPLC significantly reduces the survival promoting effect of GDNF and TGF-β consistent with the essential role of a GPI-linked GDNF alpha receptor in GDNF signal transduction. Addition both, PIPLC and TGF-β to isolated ciliary neurons, protects the GDNF alpha receptor indicating that the synergistic neurotrophic action of GDNF and TGF-β may be due to a protective action of TGF-β on the GDNF alpha receptor.

Fig. 11: The soluble proteins of chromaffin granules promote the survival of chick ciliary ganglionic neurons at a level identical to that achieved with a saturating concentration of CNTF (10 ng/ml). Addition of neutralizing antibodies to either GDNF (20 μg/ml) or the TGF-βs TGF-β1, -β2 and -β3 (10 μg/ml) significantly reduces the promoting effect of VP. Addition of both antibodies completely abolishes the neurotrophic effect of VP (0,5 ng/ml) indicating that GDNF and TGF-β are the long-sought ciliary neurotrophic proteins contained in VP.

Fig. 12: Effect of neutralizing endogenous TGF-ß in mesencephalic neuron cultures. Numbers of surviving TH-immunoreactive neurons of mesencephalic cultures (E14/DIV8) after 8 days in culture treated with FGF-2 (10 ng/ml), medium only (control), in presence or absence of neutralizing antibodies to TGF-ß1/-ß2/-ß3 (10 μg/ml). Data are given as mean ± SEM (n=3), P-values are ***P < 0.001 for increased survival as compared with control cultures and +P < 0.05 or +++P < 0.001 for decreased survival following antibody treatment.

Fig. 13: Neutralizing endogenous TGF-ß reduces the survival promoting effects of CNTF and FGF-2 on chick CG neurons. Cultures were treated with CNTF (A) or FGF-2 (B) alone (-●-) at the indicated concentrations or in combination with neutralizing antibodies (-■-) to TGF-β1, -β2, -β3 (1 μg/ml). Data are given as mean ± SEM (n=3). P-values are *P < 0.05; **P < 0.01 for decreased survival in the combination of growth factor plus anti-TGF-β as compared to growth factor-treatment alone.

Fig. 14: TGF-β induces responsiveness of chick CG neurons to CNTF, NGF and NT-3. Cultures were treated with (A) CNTF (5 or 0.3 ng/ml), Oncostatin M, LIF, IL-6 (at 10 ng/ml), or (B) NGF, NT-3, NT-4 in the absence or presence of TGF-β (2.5 ng/ml). Data are given as percent of CNTF-plateau-survival as means ± SEM (n=3). *P < 0.05, **P < 0.01 for increased survival in the combination with TGF-β3 as compared to the corresponding single factor treatment alone.

The following examples illustrate the invention:

1. **Synergistic effect between GDF-5 and BMP, respectively, with NT-3 or NGF**

Dissociated cultures of embryonic chicken dorsal root ganglia (DRG) were generated as described in details by Krieglstein and Unsicker (Neurochem. Res., 21(7) (1996) 843-850). Briefly, DRGs from white Leghorn chick embryos (day 8) were dissected in Ca^{2+}-Mg^{2+} free Hanks' balanced salt solution. After incubation in 0.08% trypsin for 15 min ganglia were dissociated by trituration. Cells were seeded in polyornithin-laminin coated 96-well microtiter plates (A/2 Costar) at a density of 1,200 cells/well. Growth factors were applied at the time of plating in a final volume of 50 ml Dulbecco's Modified Eagle's Medium supplemented with 0.25% bovine serum albumin, N1 additives and 100 U/ml penicillin. As a positive control, nerve growth factor (NGF) was used at the saturating concentration of 5 ng/ml. After 48 h of incubation at 37°C in a humidified atmosphere containing 5% CO2, cultures were fixed with 2.5% glutaraldehyde. Neuronal

cells were identified by their phase-bright and neurite-bearing morphologies and counted within 30% of the total surface area using phase contrast microscopy. In the first set of experiments we tested the survival promoting effect of several growth factors of the bone morphogenetic protein family. Dose-response analysis of GDF-5 and BMP, respectively, utilizing a wide range of serial dilutions, revealed that GDF-5 and all BMPs examined increased the number of surviving sensory neurons in a dose-dependent, saturable manner but at different magnitude (Figs. 1 and 2). For example, GDF-5 can induce an approximately two-fold increase (at a saturating concentration of 20 ng/ml) in neuronal cell numbers, corresponding to about 20% of the NGF effect (Fig. 1). BMP-4 and BMP-7 showed approximately 35% of the maximal NGF effect (Fig. 2B and D, respectively), and BMP-2, -6, -11 and -12 had also a significant effect (Fig. 2A, C, E and F, respectively).

Neurotrophic factors have been postulated to act in a finely tuned concert and sequence in determining neuronal survival. As shown in Fig. 3, addition of 2.5 ng/ml NT-3 to various concentrations of GDF-5 significantly increased DRG neuron survival above the NT-3 level indicating that NT-3 and GDF-5 can act synergistically. When added at saturating concentrations the two factors failed to increase neuronal numbers significantly above the levels of each single factor. This indicates that GDF-5 and NT-3 affect identical or largely overlapping neuron populations. In contrast, addition of GDF-5 (20 ng/ml) to NGF (5 ng/ml) significantly increased neuronal cell numbers above values obtained for each single factor (Fig. 3). This indicates that GDF-5 and NGF can promote different neuronal populations in our DRG culture system.

All other growth factors examined [brain-derived neurotrophic factor, BDNF; neurotrophin-4, NT-4; TGF-ß1 and -β3, GDNF, epidermal growth factor, EGF; transforming growth factor-a, TGF-α; fibroblast growth factor-2, FGF-2] show also synergistic or additive effects when added together with GDF-5 at any tested concentrations (Fig. 4).

As shown in Figure 5A, NGF in combination with GDF-5, BMP-4, or BMP-12 significantly increased survival of DRG neurons beyond levels maintained by the single factors. GDF-5 and BMP-12 promoted the survival of a very small neuron population when added alone. However, when combined with NGF, the increase in cell numbers was significantly higher than could be explained by simple addition. Therefore, these data indicate that GDF-5 and BMP-12 potentiate the NGF effect. The combination of BMP-4 with NGF show also significant effects. Figure 5B documents that the promoting effects of GDF-5 and BMPs are also significant for NT-3. GDF-5, BMP-2, -7 and -12 significantly augmented the promoting effect of NT-3. In the case of GDF-5 and these BMPs together with NT-3 the results show that they promote the survival of largely none-overlapping neuron popultions. Combined treatments with BMPs and BDNF, NT-4, or GDNF indicate that these factors promote survival of largely overlapping neuron populations.

The present data demonstrate a survival promoting effect of GDF-5 and BMPs on a population of peripheral sensory neurons adding to the evidence that multifunctionality of GDF-5 and BMPs comprises a capacity as neurotrophic factors. Furthermore, GDF-5 and BMPs can synergistically affect survival of neurotrophin-supported DRG neurons. Additive effects of NGF and BMPs indicate that the BMP-supported DRG subpopulation comprises NT-3- or BDNF-dependent rather than NGF-dependent DRG neurons. DRG neurons with a requirement for NT-3 belong to the category of large sensory neurons mediating proprioceptive inputs from muscle to the spinal cord. BDNF-dependent sensory neurons comprise a probably heterogeneous population. Both populations may be putative targets for GDF-5 and BMPs consistent with their localization in the early developing limb. In the context of emerging evidence that TGF-βs can synergistically act with several neurotrophins the present data indicate that such a property can also be assigned to GDF-5 and BMPs. The present data are also consistent with the notion that GDF-5 and BMPs can significantly reduce doses of neurotrophins required for supporting sensory neurons. Neurotrophins are currently in clinical trial for several forms of peripheral neuropathies. Therefore, the

pharmaceutical composition according to the present invention has a bearing on the application of neurotrophins, in particular in neuropathies responding to NT-3.

2. **Synergistic effect of TGF-β with other neurotrophic factors and neutrophins**

The neurotrophic action of GDNF on several populations of peripheral and CNS neurons essentially requires TGF-ß *in vitro* and *in vivo*.

GDNF has been proposed as a potent neurotrophic factor for cultured midbrain dopaminergic neurons, motoneurons, as well as peripheral autonomic and sensory neurons. All of the above culture systems share significant cellular complexity and/or the use of serum resulting in uncontrolled trophic conditions. A well-known constituent of almost every cell type as well as serum is TGF-ß. For example, confluent cultures of B49 cells (from which GDNF was isolated), BHK, COS cells and 3T3 fibroblasts (which are frequently used for transfection experiments) secrete within 24 h 0.2 to 0.4 ng/ml TGF-ß into their culture medium, as determined by its biological activity. Different batches of fetal calf and horse sera contain varying, but significant amounts of TGF-ß (0.1 - 0.2 ng/ml in culture media with 10% serum).

Using chick ciliary ganglionic neurons as an example, Figure 6A demonstrates that GDNF supplemented with 10% horse serum maintains neurons over a 24 h period as effectively as a saturating concentration of CNTF (5 ng/ml). However, administering culture medium that had been preincubated with neutralizing antibodies to TGF-ß (10μg/ml, known to neutralize >95% of 1 ng/ml of TGF-ß isoforms -ß1, -ß2, and -ß3) significantly reduced the effect of GDNF showing that GDNF requires TGF-ß for displaying its trophic effect. Consistent with this notion, switching from serum-containing to a fully-defined culture medium both GDNF and TGF-ß (each at the saturating amount of 2 ng/ml) showed only marginal survival promoting effects.

However, when combined the two factors promoted neurons as effectively as CNTF. In order to determine dose-response relationships required for the synergistic effect of GDNF and TGF-ß each single factor at a concentration of 2 ng/ml was titrated in combination with serial dilutions of the other one. As shown in Figure 6B 60 pg/ml of either factor combined with 2 ng/ml of the other factor represented the EC_{50}. The combination of 0.25 ng/ml and 2 ng/ml already elicited saturating effects. All isoforms of TGF-ß (TGF-ß1, -ß2, and -ß3) were consistently equipotent under the conditions used (not shown).

To investigate whether the synergistic effect of GDNF and TGF-ß also applied to other populations of peripheral neurons, identical experiments were performed using chick sensory (DRG) and paravertebral sympathetic neurons isolated from embryonic day (E) 8 embryos. As shown in Figure 6C and 6D GDNF and TGF-ß when co-administered to serum-free cultures maintained sensory and sympathetic neurons, respectively, as supported by a saturating concentration of NGF (5 ng/ml). Again, 10% horse serum substituted for TGF-ß.

To exclude that the above effects are restricted to a brief developmental time window, the same set of experiments was performed on ciliary, sensory DRG and sympathetic neurons from E10 and E12 chick embryos. Figure 7A-F shows that at all ages and on all neuron populations studied co-administration of GDNF and TGF-ß mimicked the survival promoting effect of CNTF or NGF, respectively.

As shown in Figure 8 GDNF and TGF-ß each promoted the survival of dopaminergic neurons at 160% and 200%, respectively, of untreated control cultures. Combinations of the factors did not further enhance survival consistent with the presence of endogenous TGF-ß at an amount of approximately 0.2 ng/ml. Addition of neutralizing antibodies to TGF-ß (10 μg/ml) abolished the trophic effect of GDNF. Accordingly TGF-ß is required to permit GDNF exerting its neurotrophic potential on both periphe-

ral and CNS neurons.

To prove that GDNF required TGF-ß for establishing its neurotrophic activity *in vivo*, preganglionic neurons in the spinal cord of adult rats were deprived from their adrenal chromaffin target cells using unilateral surgical destruction of the rat adrenal medulla. This type of target deprivation causes the death of all preganglionic neurons to the adrenal medulla at four weeks, as previously shown by Blottner and Baumgarten (Exp. Neurol. 118 (1992) 35-46). As can be seen in Figure 9a-c, preganglionic neurons express the GDNF receptors cRet and GFR-α1. Figure 9d shows that the substitution of the target of the preganglionic neurons by administrating 1 μg GDNF in a piece of gelfoam to the medullectomized adrenal gland fully protected the neurons after four weeks. As shown in Figure 9e, co-administration of TGF-ß-neutralizing antibodies prevented the protective effect of GDNF. This shows that the presence of endogenous TGF-ß is essential for permitting a neurotrophic effect of GDNF *in vivo*.

TGF-ß synergizes with GDNF by stabilizing or recruiting the GDNFR-α

To begin to characterize details of the specific signal transduction pathway employed by GDNF to cooperate with TGF-ß, further studies were carried out regarding the question whether activation of PI-3 kinase that has been shown as an early event in GDNF/c-ret-mediated signal transduction was involved. Figure 10A shows that the specific PI-3 kinase inhibitor wortmannin at a concentration of 0.25 μM completely abolished the survival promoting effect of GDNF in conjunction with TGF-ß on cultured ciliary neurons. Wortmannin did not interfere with the survival promoting effect of CNTF indicating that activation of PI-3 kinase is an essential event in mediating the survival promoting effect of GDNF/TGF-ß, but not that of CNTF. Furthermore, this result indicates that wortmannin did not unspecifically compromise survival.

A further question was whether TGF-ß might be involved in the stabilization and recruitment of the GPI-linked GDNFR-*α*. Phosphatidylinositol-specific phospholipase C (PIPLC) at a concentration of 0.1 U/ml was used to hydrolyse the GPI-achored receptors on dissociated ciliary neurons prior to plating. This procedure effectively reduced the survival promoting effect of CNTF (which utilizes a GPI-anchored GPAR*α*), without affecting the survival promoting effect of FGF-2 (Figure 10B). Hydrolysis of GPI-linked receptors significantly reduced the survival promoting effect of GDNF in its combination with TGF-ß. However, when the PIPLC pretreatment was conducted in the presence of TGF-ß (2 ng/ml TGF-ß1) the survival promoting effect of GDNF was maintained (Figure 10B). These data indicate an essential involvement of a GPI-linked receptor component in the neurotrophic effect of GDNF and a possible role of TGF-ß in the stabilization and/or recruitment of the alpha receptor component.

<u>TGF-ß also mediates the neurotrophic action of FGF-2, CNTF and neurotrophins</u>

Fibroblast growth factor (FGF)-2 is known to act as a neurotrophic factor for dopaminergic neurons in the ventral midbrain. Earlier studies suggested that the neurotrophic effect exerted by FGF-2 is mainly indirect and mediated by mesencephalic ganglia (Engele and Bohn, J. Neurosci. 11 (1991) 3070-3078). As TGF-ß is known to be a product of astroglial cells, it was tested whether TGF-ß-neutralizing antibodies can abolish the neurotrophic effect of FGF-2 on cultured neurons derived from the embryonic midbrain floor. Figure 12 shows that the treatment of the cultured neurons with FGF-2 (10 ng/ml) led to an 1.7fold increase in survival of the cells compared to the negative control (medium alone). In contrast, addition of antibiodies specific for TGF-ß1/-ß2/-ß3 completely abolished the survival promoting effect of FGF-2. These data show that the neurotrophic effect of FGF-2 on dopaminergic neurons in the ventral midbrain is mediated by TGF-ß.

TGF-ß was able to operate synergistically with FGF-2 and CNTF in the control of chick ciliary ganglion (CG) neuron survival. An antibody recognizing the TGF-ß isoforms -ß1/-ß2/-ß3 was employed to immunoneutralize TGF-ß in cultures of CG neurons treated with CNTF or FGF-2, respectively (Fig. 13). Neutralization of TGF-ß reduced CNTF- or FGF-2-mediated neuron survival by 40 to 60%. These data indicate that TGF-ß released from cultured CG neurons synergistically acts with exogenous neurotrophic factors to assure neuron survival.

CNTF shares receptor and signal transduction components with members of a family of neuropoetic cytokines, which include leukemia inhibiting factor (LIF), oncostatin M (OSM), and interleukin-6 (IL-6) (Stahl and Yancopoulos, J. Neurobiol. 25 (1994) 1454-1466). As shown in Figure 14A, TGF-β clearly augmented the efficacy of a non-saturating concentration of CNTF in terms of promoting CG neurons survival. OSM, LIF, and IL-6 did not support CG neurons, and further addition of TGF-β did not increase the effects of these cytokines beyond background levels. Neurotrophins are not established trophic factors for CG neurons (Collins, Brain Res. 467 (1988) 111-116). However, in combination with TGF-β, both NGF and NT-3 promoted survival at 35 to 40% of the CNTF-plateau (Fig. 14B). Although expression of trkA receptors, which permit signalling of NGF and NT-3 on CG neurons has not been shown as yet, the data presented indicate that TGF-β may cooperate neurotrophin receptor-mediated signalling on CG neurons.

Experimental Procedures

Materials

CMF: Ca^{2+}/Mg^{2+}-free Hanks' balanced salt solution, DMEM: Dulbeccos' modified Eagle's medium, and PSN were purchased from Gibco. Poly-L-ornithine, laminin, A23187, carbachol, and verapamil was purchased from Sigma, bovine serum albumin (BSA) was from Serva (Heidelberg, Germany) and PIPLC from Boehringer Mannheim (Germany).
Horse serum (HS) was purchased from Gibco, fetal calf serum (FCS) batches 1 and 2 were from PAA, FCS batches 3 and 4 were from Euro and FCS batches 5 and 6 were from PAN.

Growth factors

Growth factors were obtained from Boehringer Mannheim (NGF, 2.5 S NGF and recombinant human (rh) LIF), IC Chemikalien (recombinant rat (rr) CNTF, rh GDNF, rh Oncostatin M (OSM), rh IL-6, rh NT-3, rh NT-4 and rh BDNF) and Genetics Institute, Inc. (rh BMP-2, rh BMP-4, rh BMP-6, rh BMP-7, rh BMP-11 and rh BMP-12). For the experiments according to Fig. 5, GDF-5 was purchased form BIOPHARM, otherwise it was produced as described (Krieglstein et al., J. Neurosci. Res., 42(5) (1995) 724-732). Rh FGF-2 for the experiments according to Fig. 12 was obtained from Progen, and for all other experiments from IC Chemikalien. Lyophilized factors were resuspended in culture medium (see below) to give a final concentration of 1 μg/ml and stored in aliquots of 50-100 μl at -70°C until use.

Antibodies

The neutralizing antibody to TGFβ-1,2,3 was purchased from Genzyme and to GDNF from Santa Cruz Biotechnology.

Agarose conjugated antibodies to TGFβ-1 and to GDNF were from Santa Cruz Biotechnology. The peroxidase conjugated α-rabbit antibody was purchased from Sigma.

Animals for experiments according to Figs. 1, 3, 4, 6, 7, 8 and 11

Fertilized white Leghorns chick eggs were obtained from a local aviary and incubated in a humidified egg chamber at 37.8°C.

Animals for experiments according to Figs. 2, 5 and 12-14

Fertilized white Leghorns chick eggs were obtained from a local aviary and incubated in a humidified egg chamber at 38°C until E8.

Cell culture for experiments according to Figs. 1, 3, 4, 6, 7, 8 and 11

Assays of neurotrophic activity:

Embryonic chick ciliary (CG), dorsal root (DRG), and sympathetic (SG) ganglia at embryonic day(s) (E) 8, 10, and 12, were dissected, freed from nerve roots and connective tissue and collected in CMF. Ganglia were incubated in trypsin (ICN), washed and dissociated by trituration using fire-polished Pasteur pipettes. Cultures were set up in 96-well microtiter plates (Costar, A/2), precoated with poly-L-ornithine and laminin at a density of 1,200-1,500 cells/well in DMEM supplemented with N1 additives, 0.25% BSA, and 0.1% PSN (DME/N1) and incubated at 37°C in a 5% CO_2 incubator.
At appropriate times (CG: 24 h, DRG: 48 h, SG: 72 h) cultures were fixed by addition of 2.5% glutardialdehyde in phosphate buffered saline (PBS). Numbers of surviving neurons were determined by direct counting of 30% of the surface area using phase contrast microscopy.

Treatment with PIPLC:

Phosphatidylinositol-specific phospholipase C (PIPLC) is an enzyme that specifically cleaves glycosyl-phosphatidylinositol (GPI) linkages.

Embryonic chick ciliary ganglionic neurons (E8) were isolated and seeded as described before. Neurons were incubated for 1 h at 37°C with I) 100 mU PIPLC or II) 100 mU PIPLC + 2 ng/ml TGFβ or III) without enzyme and then growth factors were added. The number of surviving neurons was determined 24 h later.

Preparation of chromaffin cells and release studies:

The isolation of bovine adrenal medullary chromaffin cells was performed by collagenase digestion and Percoll gradient centrifugation essentially as described by Unsicker et al. (Neuroscience 5 (1980) 1445-1460). Chromaffin cells were seeded into 25 cm^2 plastic culture flasks (Falcon) at densities of 1 x 10^6 cells/ml and routinely had a purity of at least 90-95%. The culture medium consisted of DME/N1 and for stimulation experiments, the culture medium was replaced after 30 h with prewarmed stimulation buffer containing I) carbachol (100 μM) or II) carbachol (100 μM) plus verapamil (10 μM) or III) the Calcium ionophore A23187 (2 μM) or IV) no additives and incubated for 15 min at 37°C. After collection of the stimulation buffer an aliquot for determination of catecholamines by HPLC (Müller et al., J. Neurosci. Methods 4 (1981) pages 39-52) was removed, and the remainder was prepared for protein analysis.

Cell lines:

The cell lines B49, 3T3 and COS were grown in 10% FCS/DMEM with 1% PSN and the cell line BHK was set up in DMEM/F 12 with 5% FCS and 1% PSN in plastic culture flasks.

Conditioned medium of these different cell lines was collected and aliquots were stored at -80°C and then prepared for MLEC-bioassay to determine TGFβ activity.

Proteins from bovine chromaffin granules

The isolation of bovine chromaffin granules was according to the protocol by Winkler et al. (Handbook of Physiology, Section 7, Vol. 6, pp. 321-339). Granules were lysed by a freeze-thaw cycle in a 10 mM phosphate buffer (pH 7.2) and the soluble proteins were separated from membranes by ultracentrifugation at 100,000 g for 30 min. The supernatant then was dialyzed overnight against 10 mM phosphate buffer, pH 7.2 by using membrane tubing (Spectropor) with a 3.5 kDa cutoff. Aliquots were stored at -80°C.

Agarose conjugate/Western blots

To 1 ml of the stimulation buffer with or without additives from chromaffin cells 10 µl of the antibody agarose conjugate were added and incubated at 4°C overnight with mixing. The pellet was washed with PBS and then resuspended in 50 µl of electrophoresis sample buffer and boiled for 2 minutes. Samples were separated by electrophoresis on a 12.5% SDS-PAA gel and transferred to nitrocellulose membrane (Hybond, Amersham). The nitrocellulose membrane was blocked with 3% low fat milk powder/0.1% BSA in Tris buffered saline (TBS, pH 7.3), incubated with primary antibody (1:200 in 0.1% BSA/TBS) overnight at 4°C followed by peroxidase conjugated secondary antibody (1:2000 in 0.1% BSA/TBS). Finally the membrane was developed using the Amersham enhanced chemiluminescence (ECL) detection system.

Assay for TGF-β's

Determination of TGF-β activity was performed by using the mink lung epithelial cell (MLEC) (kindly provided by Dr. Rifkin, New York University, New York, USA) bioassay (Abe et al., Anal. Biochem. 216 (1994) 276-284). Transfected MLEC cultures were set up in a 96-well microtiter plate (Costar) at a density of 1.6 x 10^4 cells/well in DMEM (high glucose) with 10% FCS and geneticin (250µg/ml) and allowed to attach for 3 h at 37°C in a 5% CO_2 incubator. The medium was then replaced with 100 µl of test sample in DME/N1 (activated with HCl) and

incubated overnight at 37°C in a 5% CO_2 incubator. Cells were washed twice with PBS and lysed by using 100 µl of lysis buffer (Promega) for 2-3 h at RT. To determine TGFβ activity, 80 µl of the lysates were transferred to a test tube and analyzed using a Luminometer (Lumat, Berthold/Germany) by 100 µl injections of luciferase reagent (Promega). Luciferase activity was reported as relative light units (RLU) and all assays were performed in triplicate.

Statistics

Statistical comparisons were made with one-way ANOVA, included in the MicroCalOrigin software. Differences were considered statistically significant at * $P < 0.05$, ** $P < 0.005$, and *** $P < 0.0005$.

Cell culture for experiments according to Figs. 2, 5 and 12-14

Dissociated cultures of embryonic chicken dorsal root ganglia (DRGs) were generated as desribed in details by Krieglstein and Unsicker (Dev. Brain. Rees. 93 (1996) 10-17). Briefly, DRGs were dissected in Ca^{2+}-Mg^{2+} free Hank's balanced salt solution (CMF). After incubation in 0.08% trypsin (BioWhittaker) for 15 min, ganglia were dissociated by gentle trituration using fire-polished Pasteur pipettes. Cells in suspension (neuron/non-neuron ratio 1:2) were seeded in polyornithin-laminin coated 96-well microtiter plates (A/2 Costar) at a density of 1,200 cells/well. Growth factors were applied at the time of plating in a final volume of 50 µl Dulbecco's Modified Eagle's Medium supplemented with 0.25% bovine serum albumin, N1 additives (Bottenstein et al., Exp. Cell Res. 125 (1980) 183-190) and 100 U/ml penicillin. As a positive control, nerve growth factor (NGF) was used at the saturating concentration of 10 ng/ml. After 48 h of incubation at 37°C in a humidified atmosphere containing 5% CO_2, cultures were fixed with 2.5% glutaraldehyde in phosphate buffered saline (PBS). Neuronal cells were identified by their phase-bright and neurite-bearing morphologies and counted within 30% of the total surface area using phase contrast microscopy. All experiments were performed in at least triplicate in two independent experiments. Data are presented as mean ± SEM. Statistical comparisons

were made with student's double *t*-test, ANOVA and MicrocalOrigin software. Differences were considered statistically significant at $*P < 0.05$, $**P < 0.01$, $***P < 0.001$.

Assay for preganglionic neuron protection *in vivo*

Adrenomedullectomy was performed on adult male Hanover-Wistar rats. Preganglionic neurons in the spinal cord innervating adrenal medullary chomaffin cells were identified by retrograde tracing with Fast Blue or Fluoro-Gold (FG). Factors (1 µg each) were soaked in gelfoam (Spongostan, Ferrosan, Soeburg, Denmark) prior to implantation into unilaterally medullectomized adrenal glands. Numbers of FG-labeled preganglionic neurons were determined by cell counts of complete series of longitudinal sections through spinal cord segments T7-T10 four weeks post-surgery. Only brightly fluorescent neurons containing a clearly visible nucleus were counted. Total numbers were corrected for possible double counts of split nuclei according to Abercombie's formula. Numbers of preganglionic neurons to the adrenal medulla surviving in sham-operated animals and on the unlesioned side were set as 100%. Data are given as mean values ± SEM and the statistical significance of intergroup differences was determined by Student's *t*-test.

In situ hybridization

In situ hybridizations were performed on paraffin sections of the thoracic spinal cord essentially as described in Arumäe et al. (J. Cell Biol. 122 (1993) 1053-1065). Probes were derived from rat GFRα-1, nucleotides 294-1039, and mouse cRet, nucleotides 2534-3217. After hybridization, all sections were dipped and exposed for 2-3 weeks, counterstained with haematoxylin, air dried and embedded in DPX. No hybridization signal was detected with the probes on sense orientation.

"Cytokines having neurotrophic activity"

Claims

1. A pharmaceutical composition having neurotrophic activity, comprising a biologically active amount of at least two cytokines or functionally active derivatives or parts thereof and optionally a pharmaceutically acceptable carrier and/or diluent, wherein at least one of said cytokines is BMP, GDF, TGF-ß or GDNF.

2. The pharmaceutical composition according to claim 1, wherein the cytokines are selected from the group consisting of GDF, GDNF, TGF, activin A, BMP, BDNF, NGF, NT, EGF, EGF, CNTF and FGF.

3. The pharmaceutical composition according to claim 1 or 2, comprising GDF-5 and NGF.

4. The pharmaceutical composition according to claim 1 or 2, comprising GDF-5 and NT-3.

5. The pharmaceutical composition according to claim 1 or 2, comprising GDNF and TGF-β.

6. The pharmaceutical composition according to claim 1 or 2, comprising GDF-5 and GDNF.

7. The pharmaceutical composition according to claim 1 or 2, comprising TGF-β and FGF-2.

8. The pharmaceutical composition according to claim 1 or 2, comprising TGF-β and CNTF.

9. The pharmaceutical composition according to claim 1 or 2, comprising TGF-β and NT-3.

10. The pharmaceutical composition according to claim 1 or 2, comprising TGF-β and NGF.

11. The pharmaceutical composition according to claim 1 or 2, comprising BMP-4 and NGF.

12. The pharmaceutical composition according to claim 1 or 2, comprising BMP-12 and NGF.

13. The pharmaceutical composition according to claim 1 or 2, comprising BMP-2 and NT-3.

14. The pharmaceutical composition according to claim 1 or 2, comprising BMP-7 and NT-3.

15. The pharmaceutical composition according to claim 1 or 2, comprising BMP-12 and NT-3.

16. The pharmaceutical composition according to any one of claims 1 to 15, for treating peripheral and/or CNS-disorders in mammals.

17. The pharmaceutical composition according to claim 16, wherein the CNS-disorder is Parkinson's disease, Alzheimer's disease, ALS or other demen tious, other neurodegenerative disorders of the central nervous systems and peripheral neuropathies including diabetes, cisplatinium or other genetic or acquired peripheral nerve diseases.


neurons/well
200
150
100
50
0
GDF-6
NGF
40
20
10
5
2,5
1,2
0,6
0,3
0
ng/ml

Fig. 1


BMP-2
NGF
Neurons / well
200
150
100
50
0
20 10 5 2,5 1,2 0,6 0,3 0
ng/ml

A


BMP-4
NGF
200
150
100
50
0
20 10 5 2,5 1,2 0,6 0,3 0
ng/ml

B


BMP-6
NGF
Neurons / well
200
150
100
50
0
20 10 5 2,5 1,2 0,6 0,3 0
ng/ml

C


BMP-7
NGF
200
150
100
50
0
20 10 5 2,5 1,2 0,6 0,3 0
ng/ml

D


BMP-11
NGF
Neurons / well
200
150
100
50
0
20 10 5 2,5 1,2 0,6 0,3 0
ng/ml

E


BMP-12
NGF
200
150
100
50
0
20 10 5 2,5 1,2 0,6 0,3 0
ng/ml

F


NT-3
GDF-5 +NT-3 (2,5 ng/ml)
GDF-5
neurons/well
120
100
80
60
40
20
40
20
10
5
2,5
1,2
0,6
0,3
0
ng/ml

Fig. 3


Factor alone
+ GDF-5 20 ng/ml
Neurons/well
350
300
250
200
150
100
50
0
Control
NGF
BDNF
NT-4
TGFß1
TGFß3
GDNF
TGF-α
EGF
FGF-2

Fig. 4


Single factor (10 ng/ml)
NGF + factor
Neurons / well
350
300
250
200
150
100
50
0
GDF-5
BMP-2
BMP-4
BMP-6
BMP-7
BMP-12
NGF

A


Single factor (10 ng/ml)
NT-3 + factor
Neurons / well
350
300
250
200
150
100
50
0
GDF-5
BMP-2
BMP-4
BMP-6
BMP-7
BMP-12
NT-3

B

Fig. 5

Fig. 6 A


6/20
CG/ES-Assay
serum containing medium
serum free medium
// CG neurons/well
350
300
250
200
150
100
50
0
***
+++
***
10% HS
10% HS + anti TGFbeta-1,2,3
10% HS + GDNF
10% HS + GDNF + anti TGFbeta-1,2,3
DMEM/N1
GDNF
TGFbeta-1
GDNF + TGFbeta-1
CNTF

Fig. 6 B


GDNF (2 ng/ml) + TGFbeta-1
TGFbeta-1 (2 ng/ml) + GDNF
//CG neurons/well
110
100
90
80
70
60
50
40
30
20
2
1
0.5
0.25
0.125
0.0625
0.03125
0.01563
0.0078

Fig. 6 C


DRG/E8-Assay
serum containing medium
serum free medium
DRG neurons/well
150
100
50
0
***
+++
***
10% HS
10% HS + anti TGFbeta-1,2,3
10% HS + GDNF
10% HS + GDNF + anti TGFbeta-1,2,3
DME/N1
GDNF
TGFbeta-1
GDNF + TGFbeta-1
NGF

Fig. 6 D


SG/E8-Assay
serum containing medium
serum free medium
SG neurons/well
250
200
150
100
50
0
***
***
+++
10% HS
10% HS + anti TGFbeta-1,2,3
10% HS + GDNF
10% HS + GDNF + anti TGFbeta-1,2,3
DMEM1
GDNF
TGFbeta-1
GDNF + TGFbeta-1
NGF

Fig. 7A


CG/E10-Assay
serum containing medium
serum free medium
neurons/well
200
150
100
50
0

Fig. 7B


DRG/E10-Assay
150
100
50
0
serum containing medium
serum free medium
10% HS
10% HS
+ anti TGFbeta-1,2,3
10% HS
+ GDNF
10% HS
+ GDNF
+ anti TGFbeta-1,2,3
DMEM/H1
GDNF
TGFbeta-1
GDNF
+ TGFbeta-1
NGF

Fig. 7C


SCG10-Assay
200
150
100
50
0
serum containing medium
serum free medium
10% HS
10% HS
+ anti TGFbeta 1,2,3
10% HS
+ CNTF
10% HS
+ CNTF
+ anti TGFbeta 1,2,3
CM/GMN1
CNTF
TGFbeta1
CNTF
+ TGFbeta 1
NGF

Fig. 7D


CG/E12-Assay
150
100
50
0
neurons/well
serum containing medium
serum free medium
10% HS
10% HS + anti TGFbeta-1,2,3
10% HS + GDNF
10% HS + GDNF + anti TGFbeta-1,2,3
DMEM/N1
GDNF
TGFbeta-1
GDNF + TGFbeta-1
NGF

Fig. 7E


DRG/E12-Assay
200
150
100
50
0
neurons/well
serum containing medium
serum free medium
10% HS
10% HS + anti TGFbeta-1,2,3
10% HS + GDNF
10% HS + GDNF + anti TGFbeta-1,2,3
DMEM/N1
GDNF
TGFbeta-1
GDNF + TGFbeta-1
NGF

Fig. 7F


SG/E12-Assay
serum containing medium
serum free medium
neurons/well
150
100
50
0
10% HS
10% HS + anti TGFbeta-1,2,3
10% HS + GDNF
10% HS + GDNF + anti TGFbeta-1,2,3
DMEM/H1
GDNF
TGFbeta-1
GDNF + TGFbeta-1
HGF


TH+ neurons
1000
800
600
400
200
0
Control
GCNF
GCNF
+ anti-TGF-β
TGF-β3
GCNF
+ TGF-β3

Fig. 8


LF
IML
a
cRet mRNA
LF
IML
b
LF
IML
c
GFR-α1 mRNA
d
left side (op) **p<0.01
right side (control)
% survival of IML-neurons (T7-T10)
100
75
50
25
0
**
Cyt C
(n=4/1µg/organ)
GDNF
(n=4/1µg/organ)
e
1 µg GDNF +
5 µg anti mouse-IgG
1 µg GDNF +
5 µg anti TGFβ-IgG
***p<0.0005
% survival of IML-neurons (T7-T10)
100
75
50
25
0
***
GDNF +
control-IgG
GDNF +
anti TGFβ-IgG


CG neurons
140
120
100
80
60
40
20
0
background
GDNF
20 ng/ml
GDNF+TGF-ß
G+T+W
Wortmannin
0,25 µM

Fig. 10A


neurons
neurons + PIPLC (100mU/ml)
neurons + PIPLC (100mU/ml) +TGFbeta-1 (2ng/ml)
CG neurons/well
0
20
40
60
80
100
120
140
160
180
***
CNTF
10 ng/ml
FGF-2
10 ng/ml
GDNF + TGFbeta-1
2 ng/ml each

Fig. 10B


250
200
150
100
50
0
#ICG neurons/well
***
***
***
VP
VP + anti GDNF
VP + anti TGF-β
VP + anti GDNF + anti TGF-β
CNTF
DMEM

Fig. 11



Fig. 12

Fig. 13A



Fig. 13B



Fig. 14A



Fig. 14B



PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : A61K 38/18, 38/19

A3

(11) International Publication Number: **WO 99/15191**

(43) International Publication Date: 1 April 1999 (01.04.99)

(21) International Application Number: PCT/EP98/06004

(22) International Filing Date: 21 September 1998 (21.09.98)

(30) Priority Data:
97116373.8 19 September 1997 (19.09.97) EP

(71) Applicant *(for all designated States except US)*: BIOPHARM GMBH [DE/DE]; Czernyring 22, D–69115 Heidelberg (DE).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: UNSICKER, Klaus [DE/DE]; Köpfelweg 54, D–69118 Heidelberg (DE). POHL, Jens [DE/DE]; Bastwald 25, D–76707 Hambrücken (DE). PAULISTA, Michael [DE/DE]; Wingertstrasse 10, D–69181 Leimen (DE). BECHTOLD, Rolf [DE/DE]; Carl–Zuckmayr–Strasse 21, D–69126 Heidelberg (DE).

(74) Agent: PERREY, Ralf; Müller–Boré & Partner, Grafinger Strasse 2, D–81671 München (DE).

(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published
With international search report.
Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(88) Date of publication of the international search report:
20 May 1999 (20.05.99)

(54) Title: CYTOKINES HAVING NEUROTROPHIC ACTIVITY

(57) Abstract

The present invention relates to a pharmaceutical composition having neurotrophic activity, comprising a biologically active amount of at least two cytokines, wherein at least one of said cytokines is BMP, GDF, TGF-β or GDNF.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

INTERNATIONAL SEARCH REPORT

Inter. .onal Application No
PCT/EP 98/06004

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 A61K38/18 A61K38/19

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 97 11965 A (AMGEN INC.) 3 April 1997 see the whole document ---	1,2,16, 17
X	WO 97 19694 A (AMGEN INC.) 5 June 1997 see the whole document ---	1,2,16, 17
A	WO 92 09607 A (CELTRIX LABORATORIES) 11 June 1992 see the whole document ---	1-17
A	EP 0 105 014 A (THE UNITED STATES OF AMERICA) 4 April 1984 see the whole document -----	1-17

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

° Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
26 March 1999	01/04/1999

Name and mailing address of the ISA	Authorized officer
European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Moreau, J

Form PCT/ISA/210 (second sheet) (July 1992)

1

INTERNATIONAL SEARCH REPORT

Information on patent family members

Inte. onal Application No
PCT/EP 98/06004

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9711965 A	03-04-1997	US 5731284 A	24-03-1998
		AU 7117596 A	17-04-1997
		CA 2232789 A	03-04-1997
		EP 0852585 A	15-07-1998
WO 9719694 A	05-06-1997	US 5641750 A	24-06-1997
		AU 698062 B	22-10-1998
		AU 1059297 A	19-06-1997
		CN 1203532 A	30-12-1998
		EP 0863766 A	16-09-1998
		HU 9802374 A	01-02-1999
		NO 982275 A	29-07-1998
		US 5736516 A	07-04-1998
WO 9209607 A	11-06-1992	US 5149804 A	22-09-1992
		AT 159022 T	15-10-1997
		AU 650829 B	30-06-1994
		AU 9176491 A	25-06-1992
		DE 69127905 D	13-11-1997
		DE 69127905 T	28-05-1998
		DK 559838 T	18-05-1998
		EP 0559838 A	15-09-1993
		ES 2111631 T	16-03-1998
		GR 3025837 T	30-04-1998
		JP 6503579 T	21-04-1994
		US 5256663 A	26-10-1993
EP 105014 A	04-04-1984	AT 76299 T	15-06-1992
		AU 565347 B	10-09-1987
		AU 2120183 A	04-04-1984
		CA 1223198 A	23-06-1987
		DE 3382562 A	25-06-1992
		JP 6065680 B	24-08-1994
		US 5656587 A	12-08-1997
		WO 8401106 A	29-03-1984
		US 5705477 A	06-01-1998
		US 5104977 A	14-04-1992